Navigation Links
Inovio Pharmaceuticals Completes PENNVAX™-B HIV Vaccine Phase I Study, Demonstrates Best-in-Class T-Cell Immune Responses
Date:9/14/2011

the subjects maintained positive CD8+ T-cell responses out to six months.
  • Compared to the previously conducted HVTN 070 Phase I study, which assessed PENNVAX™-B with cytokine adjuvant IL-12 at double the dose, with four vaccinations, but without electroporation delivery, response rates in HVTN 080 with electroporation were significantly higher for both CD4+ responses (40.7%) and CD8+ T cell responses (3.6%).
  • Samples from eight placebo recipients and pre-vaccine samples from vaccine recipients were also tested and were negative for both CD4+ T-cell responses and CD8+ T-cell responses.
  • PENNVAX™-B delivered using the CELLECTRA® intramuscular electroporation delivery device with or without IL-12 was safe and generally well tolerated. There were no vaccine-related serious adverse events. Reported adverse events and injection site reactions were mild to moderate and required no treatment.

  • Dr. J. Joseph Kim, Inovio's President and CEO, said: "We are excited by the final results of the HVTN-080 study. These data are consistent with the previously announced interim results and unequivocally demonstrate the impact electroporation has on improving the immune potency of DNA vaccination. We appreciate the close collaboration with the NIH DAIDS and HVTN groups to systematically evaluate the immunogenicity of DNA immunogens together with cytokine adjuvants and delivery systems. We look forward to a continuing fruitful partnership with the HVTN and the DAIDS/NIH to further develop our HIV vaccine products to the next level."

    About the HVTNThe HIV Vaccine Trials Network (HVTN), headquartered at Fred Hutchinson Cancer Research Center in Seattle, Wash., is an international collaboration of scientists and educators searching for an effective and safe HIV vaccine. The HVTN's mission is to facilitate the process of testing preventive vaccines against HIV/AIDS. The HVTN conducts all phases of clinical trials, from evaluating
    '/>"/>

    SOURCE Inovio Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Inovio Pharmaceuticals Adds Two Medical Innovators to Its Scientific Advisory Board
    2. Inovio Pharmaceuticals to Present at Investor Conferences
    3. Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results
    4. Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I
    5. Inovio Pharmaceuticals Announces Transition of Avtar Dhillon to Non-Executive Chairman of the Board
    6. Inovio Pharmaceuticals to Present at Scientific & Industry Conferences
    7. Inovio Pharmaceuticals Subsidiary, VGX Animal Health, to Present at VetHealth Global 2011, June 14-17, 2011
    8. Inovio Pharmaceuticals to Present at American Society of Gene & Cell Therapy Annual Meeting May 18 - 21, 2011
    9. Inovio Pharmaceuticals Market-Leading Intellectual Property Recognized by MDB Capital Award
    10. Inovio Pharmaceuticals to Present at Investor Conferences
    11. Inovio Pharmaceuticals, Transgene and ChronTech Pharma to Collaborate on Heterologous Prime-Boost Therapeutic Vaccination Against Hepatitis C
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/22/2014)... , Oct. 22, 2014 AVACEN Medical ... device received 510 (k) OTC clearance by the U.S. ... 100 to be marketed over the Internet for: ... muscle spasms; and minor strains and sprains . ... The AVACEN 100 (MSRP $2495) is a sophisticated medical ...
    (Date:10/22/2014)... -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) ... focused on the development of oral drug delivery ... its Phase IIa clinical trial of ORMD-0801, the ... 1 diabetes. The trial was conducted in ... Food and Drug Administration (FDA) Investigational New Drug ...
    (Date:10/22/2014)... Influenza will affect as many as 200,000 people ... United States as high as 49,000 people.  The ... from person to person in respiratory droplets of coughs and ... death, but kills much fewer people each year than the ... fluids including sweat, saliva, blood and other bodily fluids. The ...
    Breaking Medicine Technology:AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4WholeHealth Products is proud to be releasing its Influenza A and B combo test, on the heels of the announcing of its phase 2 completion of the Rapid Ebola Test 2
    ... 2 Meeting with the FDA for the Fabry Program and Initiation ... ... Quarter, CRANBURY, N.J., Aug. 7 ... pharmacological chaperones for the treatment of human,genetic diseases, today announced financial results ...
    ... 7 The American Association of Diabetes,Educators ... conducted by Harris,Interactive highlighting communication between people ... healthcare providers. According to the,survey results, 33 ... of,dread relating to insulin injections (eight percent ...
    Cached Medicine Technology:Amicus Therapeutics Announces Second Quarter 2008 Financial Results 2Amicus Therapeutics Announces Second Quarter 2008 Financial Results 3Amicus Therapeutics Announces Second Quarter 2008 Financial Results 4Amicus Therapeutics Announces Second Quarter 2008 Financial Results 5Amicus Therapeutics Announces Second Quarter 2008 Financial Results 6Amicus Therapeutics Announces Second Quarter 2008 Financial Results 7Amicus Therapeutics Announces Second Quarter 2008 Financial Results 8Amicus Therapeutics Announces Second Quarter 2008 Financial Results 9Amicus Therapeutics Announces Second Quarter 2008 Financial Results 10Amicus Therapeutics Announces Second Quarter 2008 Financial Results 11Amicus Therapeutics Announces Second Quarter 2008 Financial Results 12New Survey Explores the Impact of Insulin Injections and Communications Between Patients and Healthcare Providers 2New Survey Explores the Impact of Insulin Injections and Communications Between Patients and Healthcare Providers 3New Survey Explores the Impact of Insulin Injections and Communications Between Patients and Healthcare Providers 4
    (Date:10/22/2014)... 22, 2014 Akeso Biomedical, Inc. ... the treatment of bacterial infections, microbial biofilms, and chronic ... its board of directors. , Dr. Sinskey ... at The Massachusetts Institute of Technology, or MIT. He ... 1968. Dr. Sinskey also holds positions as Co-Director of ...
    (Date:10/22/2014)... Haelle HealthDay Reporter , TUESDAY, ... adult men may lead to increased blood pressure, according to ... similar rise in blood pressure for young adult women or ... adult women drank lightly or moderately, their risk of high ... "This finding parallels studies in older adult men and women," ...
    (Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, 2014 (HealthDay News) ... for NBC News in Liberia has cleared the virus ... Nebraska Medical Center in Omaha, where he had been treated for ... test confirmed by the U.S. Centers for Disease Control and Prevention ... NBC News reported Tuesday night. "Recovering from Ebola ...
    (Date:10/20/2014)... The Advocator Group, LLC is proud ... for Suicide Prevention’s (AFSP) Out of the Darkness walk ... that hosts hundreds of community walks throughout the country ... to help understand and prevent suicide through not only ... , The Advocator Group shares this passion for ...
    (Date:10/20/2014)... IN (PRWEB) October 20, 2014 ... Start, a secure cloud solution that enables healthcare ... of the ultimate healthcare-specific customer relationship management (“CRM”) ... meet the unique needs of the healthcare industry, ... experience for providers and patients by combining healthcare ...
    Breaking Medicine News(10 mins):Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 3Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 2Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2
    ... , , , CARLSBAD, Calif., ... the leader in antisense therapeutics, today announced that management will present ... Conference on Tuesday, August 11, 2009, at 1:00 p.m. ET at ... audio webcast of the presentation will be available on the "Investors ...
    ... , , SPRING, ... pleased to advise the nutrition and investing community that its flagship ... corporate activities, are easily accessible by simply Googling Cholesterade(R). , ... recent updates on Go Healthy and/or its products, we are confident ...
    ... , , , , ... high-performance sports water , is targeting ... of major sporting events throughout the late summer and fall. ... cellular hydration in the most demanding environments, from professional sporting events ...
    ... ... UK have brought every major video conference endpoint manufacturer together for the ultimate in ... altogether under one roof and connect with MCU, Gateway, Firewall, Streaming & Recording infrastructure ... ...
    ... ... Web site with resources for people with disabilities coincides with Americans with Disabilities Act,s ... ... Americans with Disabilities Act, the U.S. Department of Labor has re-named and re-launched its ...
    ... , , WASHINGTON, ... announced that they have been chosen as the exclusive ... improvement program, called the IC3 Program(R) (Improving Continuous Cardiac ... Record (EHR) interfacing and data extraction process beginning with ...
    Cached Medicine News:Health News:Go Healthy's Marquis Product Cholesterade(R) at Your Fingertips on Google 2Health News:AquaHydrate, First High Performance Sports Water, Targets So Cal Sports Market With Summer Event Support 2Health News:AquaHydrate, First High Performance Sports Water, Targets So Cal Sports Market With Summer Event Support 3Health News:The World of HD Video Conferencing is Now at VideoCentric - One-stop Comparisons of Tandberg, Polycom, Lifesize, Sony, Emblaze-VCON and Aethra 2Health News:The World of HD Video Conferencing is Now at VideoCentric - One-stop Comparisons of Tandberg, Polycom, Lifesize, Sony, Emblaze-VCON and Aethra 3Health News:The World of HD Video Conferencing is Now at VideoCentric - One-stop Comparisons of Tandberg, Polycom, Lifesize, Sony, Emblaze-VCON and Aethra 4Health News:Disability.gov Adds Social Media Tools, Disability Resources and a New Design to Complement Information from 22 Federal Agencies 2Health News:Disability.gov Adds Social Media Tools, Disability Resources and a New Design to Complement Information from 22 Federal Agencies 3Health News:Featherstone Informatics Group, Inc. Named Exclusive Vendor for the American College of Cardiology's Practice-Based Data Registry Program 2
    Curved shafts with 2 mm angled platform. Wide serrated handle with dull finish....
    Curved shafts with 3.5 mm angled platform and dull finish. Wide serrated handle with dull finish....
    15 mm curved blade. 8 mm straight distal tip. Serrated on top of knife. Flat handle....
    Grooved roller, on which knife oscillates....
    Medicine Products: